Drug Trial Radar · NCT07020221
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
616
Planned (sponsor's estimate)
Start
Jun 24, 2025
Primary completion
Dec 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Verastem, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.
Conditions
- Pancreatic Ductal Adenocarcinoma
- Non Small Cell Lung Cancer
- Colorectal Cancer
- Solid Tumor, Adult
- G12D Mutated KRAS
Interventions
VS-7375Drug
VS-7375 is a highly selective oral, non-covalent, small molecule KRAS G12D (ON/OFF) inhibitor.
CetuximabDrug
Cetuximab is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR).
Carboplatin + Pemetrexed + PembrolizumabDrug
A combination therapy regimen used as a first-line treatment for advanced non-squamous non-small cell lung cancer.
Gemcitabine + Nab-paclitaxelDrug
A chemotherapy regimen used for the treatment of advanced or metastatic pancreatic ductal adenocarcinoma.
PembrolizumabDrug
Immunotherapy used as a first-line treatment for advanced non-squamous non-small cell lung cancer.
DefactinibDrug
A potent, selective, reversible inhibitor of focal adhesion kinase that also inhibits proline-rich tyrosine kinase-2
MidazolamDrug
A short-acting benzodiazepine CNS depressant that has sedative, anxiolytic, amnesic, and hypnotic effects.
RepaglinideDrug
A rapid-acting insulin secretagogue used to lower postprandial blood glucose in patients with type 2 diabetes mellitus.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: To characterize the safety, tolerability, and AE profile of escalating doses of VS-7375Time frame: Up to 2.5 years
- Part A: To identify the MTD or MFDTime frame: Cycle 1 (each cycle is 21 days)
- Part B: To evaluate the preliminary anticancer activity of the optimal VS-7375 regimenTime frame: Up to 2.5 years
- Part C: To characterize the safety, tolerability, and AE profile of VS-7375 in combination regimens.Time frame: From enrollment to the end of treatment; an average of 9 months
- Part C: To identify a recommended dose for subsequent studies of combination dosed VS-7375.Time frame: Cycle 1 (each cycle is 21 or 28 days)
- Part D: To determine the preliminary anticancer activity of the optimal regimen of VS-7375 as identified in Part CTime frame: Up to 2.5 years
- Part E: To determine the impact of VS-7375 on the PK of midazolam or repaglinideTime frame: Up to 2.5 years
- Part E: To determine the impact of VS-7375 on the PK of midazolam or repaglinideTime frame: 2.5 years
- Part E: To characterize the safety, tolerability, and AE profile of VS-7375 administered in combination with CYP3A4 and CYP2C8 substratesTime frame: 2.5 years
- Part F: Serial biopsyTime frame: Up to 2.5 years
Locations
22 sites in 4 countries. Site status is shown where the registry gives one.
Cedars-Sinai Medical Center
Los Angeles, California · Recruiting
Johns Hopkins University
Baltimore, Maryland · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
University of Michigan
Ann Arbor, Michigan · Recruiting
Washington University School of Medicine
St Louis, Missouri · Recruiting
Laura & Isaac Perlmutter Cancer Center at NYU Langone
New York, New York · Recruiting
Univ of Pennsylvania, Abramson Cancer Center
Philadelphia, Pennsylvania · Recruiting
SCRI Oncology Partners
Nashville, Tennessee · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
Huntsman Cancer Institute
Salt Lake City, Utah · Recruiting
University of Virginia
Charlottesville, Virginia · Recruiting
Virginia Cancer Specialists
Fairfax, Virginia · Recruiting
Virginia Mason Medical Center
Seattle, Washington · Recruiting
Macquarie University
Sydney, New South Wales, Australia · Recruiting
Peninsula and Southeast Oncology
Frankston, Victoria, Australia · Recruiting
Centre Leon Berard
Lyon, France · Recruiting
Centre d'Essais Precoces en Cancerologie de Marseille (CEPCM)
Marseille, France · Recruiting
Institut Curie
Paris, France · Recruiting
Vall d'Hebron Instituto de Oncología
Barcelona, Spain · Recruiting
START Rioja - Hospital Universitario San Pedro
Logroño, Spain · Recruiting
START Madrid - FJD
Madrid, Spain · Recruiting
START Madrid CIOCC - Hospital HM Sanchinarro
Madrid, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.